Trade MNPR anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Monopar Therapeutics Inc. (MNPR) is trading at US$117.56, down 0.84% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$723.04M. Over the past 52 weeks, MNPR has traded between US$38.66 and US$124.82. On Syfe you can trade MNPR with $0 commission and add it to your watchlist.
| Previous close | US$118.55 |
|---|---|
| Market cap | US$723.04M |
| 52-week range | US$38.66 – US$124.82 |
| Volume | 80.09K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Monopar Therapeutics Inc.
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Year: 2019
Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease
Jul 22, 12:55 PM · MT Newswires
Monopar Therapeutics Inc. (MNPR) stock is trading at US$117.56, -0.84% from the previous close of US$118.55.
The market cap for Monopar Therapeutics Inc. (MNPR) stock is approximately US$723.04M.
The 52-week high for Monopar Therapeutics Inc. (MNPR) stock is US$124.82.
The 52-week low for Monopar Therapeutics Inc. (MNPR) stock is US$38.66.
Monopar Therapeutics Inc. (MNPR) does not currently pay a dividend.
Stay on top of MNPR
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
